Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

NextGen Introduces Animal Biomarker Products for Development of Brain Disorder Diagnostics

Published: Friday, June 15, 2012
Last Updated: Friday, June 15, 2012
Bookmark and Share
Measures biomarkers in rat cerebrospinal fluid.

NextGen Group Plc has announced the commercialization of a new assay for the identification of diagnostic biomarkers in brain disorders in animal models.

The assay measures protein markers in rat cerebrospinal fluid and will expand the product offering of NextGen’s contract research subsidiary, NextGen Sciences Inc.

An assay is the procedure for measuring the effects of a chemical in an organism. For example, assays are used to discover biomarkers which are in turn used to identify the existence and progression of a disease.

Biomarkers are used in clinical trials to aid in patient selection and to evaluate the effectiveness of a drug. They are also used in the development of companion diagnostics that will drive the growth of the personalized medicine market.

There is a significant need for biomarkers to monitor and diagnose central nervous system disorders, such as dementia, Parkinson’s disease and neuropsychological disorders, within the patient care and drug development industries.

NextGen’s “CSFassay-rat A.1.0” product is capable of measuring 62 cerebrospinal fluid (CSF) proteins simultaneously that have been identified as likely biomarkers in various central nervous system (CNS) disorders.

Barry McAleer, PhD, CEO of NextGen Sciences Inc says: “Assays that can discover biomarkers in animal models will enhance the drug development process within the pharmaceutical industry and could lead to reduced attrition in the drug development process. With the introduction of the CSFassay-rat A.1.0 we have delivered on the first phase of ongoing product development plans that enables us to support and enhance the pre-clinical drug development programs of our customers. This new product and those currently in development are already attracting interest in the marketplace and we are in discussions with a number of clients who wish to use these assays in their R&D programmes.”

The release of the CSFassay-rat A.1.0 product is the first assay in a family of animal model CSF assays and provides confirmation of NextGen’s previously stated intention to deliver assays in animal species.

Explains Barry McAleer: “Our customers can choose to employ our current assay products in their diagnostic biomarker programs or they can ask us to make custom assays for them, in multiple species, in CSF and plasma and for hundreds of proteins. We can do it in just a matter of weeks.

“With our previously released human CSF and plasma assays we continue to widen the landscape for our customers to find diagnostic biomarkers in different animal species models. These biomarkers can be combined in a single assay that can be employed through the pre-clinical and clinical stages of drug development. This improves the chances for diagnostic markers to proceed all the way through to companion diagnostics and to aid the personalization of medicine.”

NextGen uses mass spectrometry (a technique for specifically identifying and quantifying biomarkers in samples) as its core technology to discover highly specific protein biomarkers that can be used for diagnostic purposes.

“The speed with which we can develop these assays (three times faster than our previous assays), in multiple species and with hundreds of analytes, signifies a huge step forward in the speed with which we can look to grow our business.”

Klaus Rosenau, Chairman of NextGen Group PLC, explains: “We continue to strengthen our position towards becoming be a leader in providing high quality diagnostic biomarker assays. We intend to increase the speed with which we can exploit our technology and products within the project engine pipeline of the NextGen Sciences Dx business. Projects are already at different stages of development as we pursue our ambition to generate further intellectual property and seek out biomarker sale/licencing/testing routes to build shareholder value.”

In 2010, the total global market for biomarkers was an estimated $13.5 billion and is expected to grow to nearly $33.3 billion by the end of 2015 (BCC Research).

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NextGen's New Diagnostics Company Established
Progress on filing of intellectual property expected in the next six months.
Monday, February 27, 2012
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos